SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

June 9, 2020

By Grant M. Gallagher

Video

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos

Related Content

Early Detection of COVID Infection? There's Possibly an App For That

Early Detection of COVID Infection? There's Possibly an App For That

Kenneth Bender, PharmD, MA

A Passion for Infectious Disease Education and Communication

A Passion for Infectious Disease Education and Communication

Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD;Timothy Gauthier, PharmD, BCPS, BCIDP

The group includes Michael Peluso, MD, MHS; Amy Proal, PhD; and David Putrino, PhD, and will study monoclonal antibody therapies targeting persistent spike protein.

Invivyd Forms SPEAR Study Group to Investigate Pemivibart for Long COVID and Post-Vaccination Syndrome

From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella Pneumoniae

From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella Pneumoniae

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc ;Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS

December 23rd 2024

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 vs Placebo

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 vs Placebo

ACIP June 2025: COVID-19 Trends, Vaccine Updates, and Targeted Recommendations

ACIP June 2025: COVID-19 Trends, Vaccine Updates, and Targeted Recommendations

Related Content

Early Detection of COVID Infection? There's Possibly an App For That

Early Detection of COVID Infection? There's Possibly an App For That

Kenneth Bender, PharmD, MA

A Passion for Infectious Disease Education and Communication

A Passion for Infectious Disease Education and Communication

Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD;Timothy Gauthier, PharmD, BCPS, BCIDP

The group includes Michael Peluso, MD, MHS; Amy Proal, PhD; and David Putrino, PhD, and will study monoclonal antibody therapies targeting persistent spike protein.

Invivyd Forms SPEAR Study Group to Investigate Pemivibart for Long COVID and Post-Vaccination Syndrome

From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella Pneumoniae

From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella Pneumoniae

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc ;Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS

December 23rd 2024

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 vs Placebo

Monoclonal Antibody Shows 84% Relative Risk Reduction of Symptomatic COVID-19 vs Placebo

ACIP June 2025: COVID-19 Trends, Vaccine Updates, and Targeted Recommendations

ACIP June 2025: COVID-19 Trends, Vaccine Updates, and Targeted Recommendations

Contagion, Spring 2025 Digital Edition

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.